.US Zulassung im 3Q / 4Q 2010..Unentdeckte Aktie
Seite 1 von 1 Neuester Beitrag: 25.04.21 02:49 | ||||
| Eröffnet am: | 20.08.10 19:28 | von: Biotechmaste. | Anzahl Beiträge: | 15 |
| Neuester Beitrag: | 25.04.21 02:49 | von: Katjavekya | Leser gesamt: | 9.420 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
Hab eben 10000stück gekauft .Viel Glück
IVAX Diagnostics (AMEX: IVD)
Marktkap: 15.24M
Kurs: 0,55 $
Shares Outstanding: 27.65M
Float: 7.50M
Dr. Struby continued, “Our efforts with respect to our 510(k) premarket submission filing with the U.S. Food and Drug Administration for the Mago® 4S, our next-generation fully automated ELISA system for autoimmune and infectious disease testing, are progressing, and we continue to expect to receive regulatory approval from the FDA and launch the product during the fourth quarter of 2010. Following the receipt of all required regulatory approvals and the subsequent commercial launch of the product, we expect the Mago® 4S will provide a flexible, efficient and cost-effective solution to high-performance laboratories, and will be our primary platform for marketing our kits in the U.S.”
IVAX Diagnostics Reports Purchase of Majority Stockholders' Interests
Press Release Source: IVAX Diagnostics, Inc. On Wednesday September 1, 2010, 11:06 am
MIAMI--(BUSINESS WIRE)--IVAX Diagnostics, Inc. (NYSE Amex: IVD), a fully integrated in vitro diagnostics company, announced that today ERBA Diagnostics Mannheim GmbH purchased from a group controlled by Patrice Debregeas and Paul Kennedy all of the approximately 72% of the outstanding shares of IVAX Diagnostics owned by their group for $0.75 per share, or an aggregate purchase price of approximately $15 million. ERBA Diagnostics Mannheim, headquartered in Mannheim, Germany, is an emerging player in the in vitro diagnostics market.
http://southflorida.bizjournals.com/southflorida/...26.html?ana=yfcpc
A German company has purchased most of the outstanding stock of Miami-based Ivax Diagnostics in a $15 million deal.
The local company (AMEX: IVD) makes and distributes in vitro diagnostic kits, as does its controlling shareholder, Erba Diagnostics Mannheim. The German company purchased all of the shares controlled by Patrice Debregeas and Paul Kennedy – about 72 percent of the company’s common stock. It paid 75 cents a share.
Debregeas is the chairman of Ivax Diagnostics. Kennedy is on its board and was once its president and CEO.
It appears that the pair made a profit on the sale to Erba. In September 2008, Kennedy and Debregeas paid $14 million, or 70 cents a share, to acquire 72 percent of Ivax Diagnostics from Teva Pharmaceutical Industries.
Company officials declined to comment further.
Ivax Diagnostics recently reported a loss of $1.3 million on revenue of $2.3 million in the second quarter.
According to Erba’s website, it markets its products in 50 countries in Latin America, Europe, Africa and Asia. It does not mention distribution in the U.S.
Ivax Diagnostics shares were up 8 cents, or nearly 15 percent, to 63 cents in midday trading. The 52-week high was 80 cents on April 13. The 52-week low was 41 cents on Jan. 4.
Read more: German company gains control of Ivax Diagnostics - South Florida Business Journal
http://ih.advfn.com/...chart&s=A%5EIVD&p=0&t=19&vol=1
Redest du von dollar cent?
Euro Kurse gibt es ja leider nur 2-3 mal am Tag.
Da die "Stamm Aktien" der Gründer/CEO nun für 75c erworben wurden sollten wir min. diesen Kurs in Kürze auch am Markt sehen.
dermako
Ich kaufe Aktien gründsätzlich immer an den Heimatbörsen .Viel Glück
@gunter
das musst du selber für dich entscheiden
http://www.barchart.com/cheatsheet.php?sym=IVD
Die Ergebnisse des 3. Quartals waren prima, und der Aktienfloat beträgt nur
ca. 7 Millionen Stück.
Das Volumen der letzten Tage lässt weiter hoffen ..........................
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Erba Diagnostics |